Compare AbCellera Biologics Inc (ABCL) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Yum! Brands, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.16 (market cap $2.35B), while Yum! Brands, Inc. trades at $163.5 (market cap $46.16B). The key difference: Yum! Brands, Inc. is far larger — about 19.6× AbCellera Biologics Inc's market cap, and Yum! Brands, Inc. pays a 1.79% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | YUM | |
|---|---|---|
Market Cap | $2.35B | $46.16B |
Sector | Health | Consumer Cyclical |
52-Week High | $8.12 | $168.16 |
52-Week Low | $2.78 | $138.21 |
Enterprise Value | $1.99B | $57.43B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
YUM trades at $167.49, up 1.68% today, near its consensus price target of $174.00. The stock shows a bullish technical trend with strong moving averages, though RSI indicates potential overbought conditions. Fundamentals are solid with revenue growth from $7.5B in 2024 to $8.2B in 2025 and a net income margin of 20.48%. Recent news highlights the $2.7 billion sale of Pizza Hut, aimed at streamlining operations and funding a $4 billion share repurchase, signaling strategic focus on KFC and Taco Bell.
The outlook for YUM is cautiously optimistic, supported by earnings beats and strategic divestiture, but high debt levels and competitive pressures pose risks. Analyst consensus leans hold with a 37.25% buy rating, suggesting moderate upside potential. Investors should weigh the benefits of capital returns against execution risks in a challenging consumer discretionary environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
